Related Experiment Video

Updated: Mar 22, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K

The therapeutic potential of mTOR inhibitors in breast cancer

Linda S Steelman1, Alberto M Martelli2, Lucio Cocco2

  • 1Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA.

British Journal of Clinical Pharmacology
|April 10, 2016
PubMed

Insights

Rapamycin and its analogs (rapalogs) target the mTORC1 pathway, impacting cell growth and protein translation. Recent research explores their use in overcoming endocrine resistance in breast cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Rapamycin and rapalogs are established immunosuppressants used in organ transplantation.
  • The mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) regulates cell growth and protein translation via substrates like p70S6K and 4E-BP1.
  • mTORC1 pathway dysregulation, often due to genetic alterations in growth factor receptors, kinases, or phosphatases, is implicated in various cancers.

Purpose of the Study:

  • To review recent basic and clinical research on rapamycin and rapalogs.
  • To evaluate novel therapeutic strategies involving rapalogs, particularly in endocrine-resistant breast cancer.
  • To summarize the role of mTORC1 in cellular regulation and its therapeutic implications.

Main Methods:

  • Review of existing scientific literature and clinical trial data.
  • Analysis of mTORC1 pathway components and their substrates.
  • Evaluation of combination therapies involving rapalogs and hormonal agents.

Main Results:

  • Rapalogs demonstrate efficacy in preventing allograft rejection.
  • Dysregulation of mTORC1 is linked to cancer development and progression.
  • Combined treatment with rapalogs (e.g., everolimus) and aromatase inhibitors (e.g., exemestane) is FDA-approved for specific breast cancer cases.
  • Rapalogs show potential in overcoming endocrine resistance in estrogen receptor-positive breast cancer.

Conclusions:

  • The mTORC1 pathway is a critical regulator of cell growth and a target for cancer therapy.
  • Rapalogs represent a valuable therapeutic option for patients with endocrine-resistant breast cancer.
  • Further research into novel therapeutic approaches targeting the mTORC1 pathway is warranted.
Keywords:
drug resistanceendocrine resistanceeverolimusexemestanemetastasisrapamycin

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.7K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K